1,2 The results are consistent with actions taken by the European Medicines Agency (EMA) in June 2025, when the agency classified NAION as a very rare side effect of semaglutide and recommended product labeling updates. Epidemiologic data reviewed by the EMA suggested an approximately twofold increased risk in adults with type 2 diabetes, corresponding to roughly one additional case per 10,000 person-years of treatment. The agency advised that patients with sudden vision loss or rapidly worsening eyesight seek immediate medical attention and discontinue treatment if NAION is confirmed. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation Study strengths Methodologically, the VA study offers several strengths: The analysis leveraged the largest integrated health care system in the United States, with medication exposure confirmed through pharmacy dispensing records rather than prescription data alone
Some users are non-responders to GLP-1 therapy at standard doses and require dose titration to achieve noticeable appetite effects
The C -terminally truncated PMCA2a is the only isoform detected in the stereocilia of HCs (Furuta et al., 1998
Crucially, the individual component would incorporate key personal variables such as genetic polymorphisms (e.g., in Nrf2 or metabolic enzyme genes), gut microbiome composition (which metabolizes many hormetins), age, and baseline health status
In the real world, environmental toxins, your diet, stress, and other lifestyle issues have disabled the checks and balances of this system, encouraging your body to make more of the pro-inflammatory prostaglandins and less of the anti-inflammatory ones
LifeRx is available in all 50 states with no restrictions
